As of October 27, 2026, City Therapeutics, Inc. is a publicly traded company (Nasdaq: CTY). The largest holder reporting an active stake on Schedule 13D is ARCH Venture Fund XII, L.P., at 25.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Invus Public Equities, L.P. (8.1%), Viking Global (7%) (Schedule 13D, October 26, 2026).
About to sign with, pay or invest in City Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is City Therapeutics, Inc. a real, registered company?
- City Therapeutics, Inc. files with the SEC under CIK 2143850 (its SEC filings).
- Its shares are listed under the ticker CTY on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under City Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-27).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names ARCH Venture Fund XII, L.P. (filed 2026-10-26).
Who are City Therapeutics, Inc.'s owners and officers?
City Therapeutics, Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Pharmaceutical Preparations (Schedule 13D, 2026-10-26).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D, 2026-10-26 | Arch Venture Fund Xii, L.P. | 25.6% |
| Schedule 13G, 2026-10-26 | Viking Global Investors LP | 7% |
| Schedule 13G, 2026-10-22 | Invus Public Equities, L.P. | 8.1% |
Want the whole picture on City Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on City Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on City Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own City Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- ARCH Venture Partners XII, L.P., a 10% owner: 13,692,507 shares, held indirectly through By ARCH Venture Fund XII, L.P., on a joint filing (Form 4, 2026-10-19).
- ARCH Venture Fund XII, L.P., a 10% owner: 13,692,507 shares, held indirectly through By ARCH Venture Fund XII, L.P., on a joint filing (Form 4, 2026-10-19).
- , a 10% owner: 13,692,507 shares, held indirectly through By ARCH Venture Fund XII, L.P., on a joint filing (Form 4, 2026-10-19).
- , a 10% owner: 13,692,507 shares, held indirectly through By ARCH Venture Fund XII, L.P., on a joint filing (Form 4, 2026-10-19).
- ARCH Venture Partners XII, LLC, a 10% owner: 13,692,507 shares, held indirectly through By ARCH Venture Fund XII, L.P., on a joint filing (Form 4, 2026-10-19).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has City Therapeutics, Inc. raised?
Latest IPO step: City Therapeutics, Inc. filed its final IPO prospectus, ticker CTY (424B4, 2026-10-16).
IPO filings: 424B4, 2026-10-16, S-1/A, 2026-10-09, S-1, 2026-09-24; ticker CTY on Nasdaq Global Market.
Keep reading
More on City Therapeutics, Inc. and the records around it.
City Therapeutics, Inc. elsewhere on the record
- IPO filing Oct 2026
Companies that share a holder
- ARCH Venture Fund XII, L.P. also filed stake reports on 5 other companies: Parabilis Medicines, Inc. (Aug 2026), Seaport Therapeutics, Inc. (May 2026), Neumora Therapeutics, Inc. (Apr 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026), enGene Holdings Inc. (Aug 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026), Inhibrx Biosciences, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/city-therapeutics